Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Faubion, 2001, The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study, Gastroenterology, 121, 255, 10.1053/gast.2001.26279 Munkholm, 1994, Frequency of glucocorticoid resistance and dependency in Crohn's disease, Gut, 35, 360, 10.1136/gut.35.3.360 Steinhart, 2000, Maintenance therapy in Crohn's disease, Can J Gastroenterol Update Liver Inflammatory Bowel Dis (ULIBD), 14, 23 Sandborn, 2000, Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease, Cochrane Database Syst Rev, 2, CD000545 Feagan, 1995, Methotrexate for the treatment of Crohn's disease, N Engl J Med, 332, 292, 10.1056/NEJM199502023320503 Kindler, 1989, The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection, Cell, 56, 731, 10.1016/0092-8674(89)90676-4 Braegger, 1992, Tumour necrosis factor alpha in stool as a marker of intestinal inflammation, Lancet, 339, 89, 10.1016/0140-6736(92)90999-J Beese, 1994, Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease, Gastroenterology, 106, 1455, 10.1016/0016-5085(94)90398-0 MacDonald, 1990, Tumor necrosis factor-alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine, Clin Exp Immunol, 81, 301, 10.1111/j.1365-2249.1990.tb03334.x Schreiber, 1999, Tumour necrosis factor α and interleukin 1 β in relapse of Crohn's disease, Lancet, 359, 459, 10.1016/S0140-6736(98)03339-X Knight, 1993, Construction and initial characterization of a mouse-human chimeric anti-TNF antibody, Mol Immunol, 30, 1443, 10.1016/0161-5890(93)90106-L Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502 Cohen, 2000, Infliximab in Crohn's disease: first anniversary clinical experience, Am J Gastroenterol, 95, 3469, 10.1111/j.1572-0241.2000.03363.x Ricart, 2001, Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients, Am J Gastroenterol, 96, 722, 10.1111/j.1572-0241.2001.03612.x Nikolaus, 2000, Mechanisms in failure of infliximab for Crohn's disease, Lancet, 356, 1475, 10.1016/S0140-6736(00)02871-3 Rutgeerts, 1999, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, Gastroenterology, 117, 761, 10.1016/S0016-5085(99)70332-X Best, 1976, Development of a Crohn's Disease Activity Index: National Cooperative Crohn's Disease Study, Gastroenterology, 70, 439, 10.1016/S0016-5085(76)80163-1 Irvine, 1994, Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease, Gastroenterology, 106, 287, 10.1016/0016-5085(94)90585-1 Keane, 2001, Tuberculosis associated with infliximab, a TNF-alpha neutralizing agent, N Engl J Med, 345, 1098, 10.1056/NEJMoa011110 Baker, 2001, Tuberculosis occurring in patients receiving the anti-TNF agent infliximab, Arthritis Rheum, 44, S105 Toy, 2000, Complete bowel obstruction following initial response to infliximab therapy for Crohn's disease: a series of a newly described complication, Gastroenterology, 118, A569, 10.1016/S0016-5085(00)84412-1 Maini, 1998, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum, 41, 1552, 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W Schaible, 2000, Long term safety of infliximab, Can J Gastroenterol Update Liver Inflammatory Bowel Dis (ULIBD), 14, 29 Sachmechian, 2001, Malignancy following Remicade therapy: incidence and characteristics, Gastroenterology, 120, A619, 10.1016/S0016-5085(08)83081-8 Bernstein, 2001, Cancer risk in patients with inflammatory bowel disease, Cancer, 91, 854, 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z Greenstein, 1991, Lymphoma in inflammatory bowel disease, Cancer, 69, 1119, 10.1002/cncr.2820690510 Ekborn, 1990, Extracolonic malignancies in inflammatory bowel disease, Cancer, 67, 2015